TOPIRAMATE FOR MIGRAINE PROPHYLAXIS AMONG CHILDREN AGED 5 TO 15 YEARS

Authors

  • Muhammad Khalil Surani Department of Peadiatric Medicine,Children Hospital & The Institute of Child Health, Multan
  • Muhammad Yousuf Clinical Fellow Peads Neurology, Children Hospital & The Institute of Child Health, Multan
  • Naveed Anjum Department of Peads Neurology, Children Hospital & The Institute of Child Health, Multan
  • Sabiha Khan Department of Paediatric Medicine, Fatimah Jinnah Hospital, Multan
  • Gul Hasan Senior Registrar, Department of Peadiatric Medicine, Children Hospital & The Institute of Child Health, Multan
  • Sajid Hussain Department of Paediatric Medicine, Children Hospital & The Institute of Child Health, Multan

Abstract

Background: Migraine is known to be a common neurological disorder among children. Newer anti-epileptic agents like topiramate (TPM) have shown to decrease the frequency of headache but not much work about safety and efficacy of TPM is seen in the paediatric population with migraine. This study was aimed to find out the efficacy and safety of TMP for migraine prophylaxis among children aged 5-15 years. Methods: A total of 132 children having migraine headache according to ICHD-II criterion for duration of at least 6 months, from 5-15 years of age were enrolled. Frequency of headache, severity of headache and duration of headache were compared before and after 3 months of TPM treatment. Side effects of TPM treatment were also observed. Results: In a total of 132 children, 80 (60.6%) were female and 52 (39.4%) males. Mean age was 9.52±2.5 years. Good response of TPM treatment was observed in 102 (77.3%) children. Significant decrease (p value <0.05) was noted in headache frequency, severity and duration following TPM treatment. No serious side effects of TPM treatment were noted. Conclusion: Topiramate is noted to be effective and safe for migraine prophylaxis among children. Reduction in headache frequency, severity as well as duration and disability scores are recorded after TPM treatment.

Author Biographies

Muhammad Khalil Surani, Department of Peadiatric Medicine,Children Hospital & The Institute of Child Health, Multan

MBBS, FCPS (Paediatric Medicine)

Senior Registrar, Department of Peads Medicine, Children Hospital & The Institute of Child Health, Multan

Muhammad Yousuf, Clinical Fellow Peads Neurology, Children Hospital & The Institute of Child Health, Multan

Clinical Fellow Peads Neurology
Children Hospital & The Institute of Child Health, Multan

Naveed Anjum, Department of Peads Neurology, Children Hospital & The Institute of Child Health, Multan

MBBS, FCPS (Peads Medicine), FCPS (Peads Neurology)

Assistant Professor, Department of Peads Neurology,

Children Hospital & The Institute of Child Health, Multan.

Sabiha Khan, Department of Paediatric Medicine, Fatimah Jinnah Hospital, Multan

MBBS, FCPS (Pediatric Medicine)

Women Medical Officer, Fatimah Jinnah Hospital, Multan.

Gul Hasan, Senior Registrar, Department of Peadiatric Medicine, Children Hospital & The Institute of Child Health, Multan

MBBS, FCPS (Paediatric Medicine)

Seniir Registrar, Department of Peadiatric Medicine,

Children Hospital & The Institute of Child Health, Multan.

Sajid Hussain, Department of Paediatric Medicine, Children Hospital & The Institute of Child Health, Multan

MBBS, MCPS (Pediatric)

Medical Officer, 

Children Hospital & The Institute of Child Health, Multan

References

Teleanu RT, Vladacenco O, Teleanu D, Epure DA. Treatment of Pediatric Migraine: a Review. Maedica (Bucur) 2016;11(2):136-43.

Hershey AD. Migraine. In: Kliegman RM, Stanton BF, Schor NF, St Geme JW, Behrman RE, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Saunders, 2011; p.2040-5.

Barnes N, Millman G, James E. Migraine headache in children. Clin Evid 2006;15(15):469-75.

Ottman R, Hong S, Lipton RB. Validity of family history data on severe headache and migraine. Neurology 1993;43(10):1954-60.

Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd ed. Cephalalgia 2004;24(Suppl-1):9-160.

Hershey AD, Winner PK. Pediatric migraine: recognition and treatment. J Am Osteopath Assoc 2005;105(4 Suppl 2):2S-8.

Lewis DW, Scott D, Rendin V. Treatment of pediatric headache. Expert Opin Pharmacother 2002;3(10):1433-42.

Pietrobon D. Migraine: New molecular mechanisms. Neuroscientist 2005;11(4):373-86.

Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Epilepsia 1997;38(Suppl 1):S24-7.

Minton GC, Miller AD, Bookstaver PB, Love BL. Topiramate: Safety and efficacy of its use in the prevention and treatment of migraine. J Cent Nerv Syst Dis 2011;3:155-68.

Winner P. Overview of pediatric headache. Curr Treat Options Neurol 2004;6(6):471-87.

Cruz MJ, Valencia I, Legido A, Kothare SV, Khurana DS, Yum S, et al. Efficacy and tolerability of topiramate in pediatric migraine. Pediatr Neurol 2009;41(3):167-70.

Fallah R. Topiramate as a new antiepileptic drug in epileptic children in Iran. Indian J Pediatr 2006;73(12):1073-5.

Fallah R, Karbasi SA, Shajari A, Fromandi M. The efficacy and safety of topiramate for prophylaxis of migraine in children. Iran J Child Neurol 2013;7(4):7-11.

Hershey AD, Powers SW, Vockell ALB, LeCates SL, Kabbouche MA, Maynard MK. PedMIDAS: Development of a questionnaire to assess disability of migraines in children. Neurology 2001;57(11):2034-9.

Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990;13(4):227-36.

Eiland LS. Anticonvulsant use for prophylaxis of the pediatric migraine. J Pediatr Health Care 2007;21(6):392-5.

Lewis D, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache 2004;44(3):230-7.

Freitag FG, Schloemer F, Schumate D. Recent Developments in the Treatment of Migraine in Children and Adolescents. Headache Pain Manag 2016;1:1-8.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1261-73.

Valencia I, Fons C, Kothare SV, Khurana DS, Yum S, Hardison HH, et al. Efficacy and tolerability of topiramate in children younger than 2 years old. J Child Neurol 2005;20(8):667-9.

Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate Pediatric Migraine Study Investigators. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005;45(10):1304-12.

Lewis D, Winner P, Saper J, Ness S, Polverejan E, Wang S, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 2009;123(3):924-34.

Borzy JC, Koch TK, Schimschock JR. Effectiveness of topiramate in the treatment of pediatric chronic daily headache. Pediatr Neurol 2005;33(5):314-6.

Saleem SF, Qaisar I, Rehman A. Topiramate for migraine prophylaxis in children. Med Forum 2019;30(3):71-4.

Unalp A, Uran N, Oztürk A. Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. J Child Neurol 2008;23(12):1377-81.

Lakshmi CV, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol 2007;22(7):829-35.

Campistol J, Campos J, Casas C, Herranz JL. Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 2005;20(3):251-3.

Downloads

Published

2021-06-30

How to Cite

Surani, M. K., Yousuf, M., Anjum, N., Khan, S., Hasan, G., & Hussain, S. (2021). TOPIRAMATE FOR MIGRAINE PROPHYLAXIS AMONG CHILDREN AGED 5 TO 15 YEARS. Journal of Ayub Medical College Abbottabad, 33(3), 480–483. Retrieved from https://jamc.ayubmed.edu.pk/index.php/jamc/article/view/7299

Issue

Vol. 33 No. 3 (2021): Journal of Ayub Medical College Abbottabad

Section

ORIGINAL ARTICLE

License

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.